Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ASH 2019

7 - 10 Dec 2019
Orlando, Orlando, United States of America
VITAL trial: Safety of vosaroxin and infusional cytarabine for frontline treatme...
Dr Stephen Strickland - Vanderbilt University Medical Center, Nashville, USA
VITAL trial: Safety of vosaroxin and infusional cytarabine for frontline treatment of AML ( Dr Stephen Strickland - Vanderbilt University Medical Center, Nashville, USA )
27 Jan 2020
Are remissions for AML patients 'better' after daunorubicin and cytarabine lipos...
Prof Daniel Ryan - University of Rochester, Rochester, USA
Are remissions for AML patients 'better' after daunorubicin and cytarabine liposome injection ( Prof Daniel Ryan - University of Rochester, Rochester, USA )
24 Dec 2019
Is enasidenib plus azacitidine better than with azacitidine alone for AML patien...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
Is enasidenib plus azacitidine better than with azacitidine alone for AML patients? ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
24 Dec 2019
PET-Directed therapy for early-stage diffuse large B-cell lymphoma
Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA
PET-Directed therapy for early-stage diffuse large B-cell lymphoma ( Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA )
24 Dec 2019
Lenalidomide maintenance for transplant eligible and transplant ineligible newly...
Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )
24 Dec 2019
Dasatinib vs imatinib in the treatment of paediatric ALL
Dr Shuhong Shen - National Children's Medical Center, Shanghai, China
Dasatinib vs imatinib in the treatment of paediatric ALL ( Dr Shuhong Shen - National Children's Medical Center, Shanghai, China )
24 Dec 2019
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in...
Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switz...
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans ( Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland )
19 Dec 2019
Prognostic impact of chromosomal abnormalities and copy number alterations in B-...
Prof Anthony Moorman - Newcastle University, Newcastle, UK
Prognostic impact of chromosomal abnormalities and copy number alterations in B-cell precursor ALL treated on UKALL14 ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
19 Dec 2019
Long-term outcomes of subjects with EBV driven PTLD following solid organ or all...
Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA
Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel ( Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA )
19 Dec 2019
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT afte...
Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )
19 Dec 2019
Outcomes in patients with therapy-Related AML who achieved remission with CPX-35...
Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, US...
Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
19 Dec 2019
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML tr...
Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
18 Dec 2019
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from ...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019
LYRA: Maintenance therapy with daratumumab improves depth of response and achiev...
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
LYRA: Maintenance therapy with daratumumab improves depth of response and achieves durable remissions in MM patients ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )
17 Dec 2019
KRd consolidation in MM patients with a positive PET-CT after standard first-lin...
Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway
KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial ( Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway )
17 Dec 2019
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzu...
Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene...
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL ( Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene, USA )
17 Dec 2019
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell l...
Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma ( Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA )
17 Dec 2019
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory c...
Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia ( Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center )
17 Dec 2019
GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy?
Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA
GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy? ( Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA )
17 Dec 2019
Predicting early relapse in transplant-eligible MM patients using baseline progn...
Dr Francesca Gay - University of Torino, Torino, Italy
Predicting early relapse in transplant-eligible MM patients using baseline prognostic features and MRD negativity ( Dr Francesca Gay - University of Torino, Torino, Italy )
17 Dec 2019
Using multiparameter flow cytometry and next generation sequencing to evaluate M...
Dr Francesca Gay - University of Torino, Torino, Italy
Using multiparameter flow cytometry and next generation sequencing to evaluate MRD in NDMM patients from the FORTE trial ( Dr Francesca Gay - University of Torino, Torino, Italy )
17 Dec 2019
Complete remission after induction chemotherapy determines clinical efficacy of ...
Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden
Complete remission after induction chemotherapy determines clinical efficacy of relapse-preventive immunotherapy in AML ( Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden )
17 Dec 2019
FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patie...
Prof David Cairns - University of Leeds, Leeds, UK
FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM ( Prof David Cairns - University of Leeds, Leeds, UK )
17 Dec 2019
Myeloma highlights from ASH 2019
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Myeloma highlights from ASH 2019 ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
13 Dec 2019
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
13 Dec 2019
FLT3-inhibition in infants with acute lymphoblastic leukaemia
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
FLT3-inhibition in infants with acute lymphoblastic leukaemia ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )
13 Dec 2019
Chronic lymphocytic leukaemia highlights from ASH 2019
Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia
Chronic lymphocytic leukaemia highlights from ASH 2019 ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )
13 Dec 2019
Benefits of apixaban among venous thromboembolism patients with active cancer
Dr Alexander Cohen - Guys and St Thomas, London, UK
Benefits of apixaban among venous thromboembolism patients with active cancer ( Dr Alexander Cohen - Guys and St Thomas, London, UK )
13 Dec 2019
Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelp...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-negative ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
13 Dec 2019
Dasatinib vs imatinib for paediatric Ph ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Dasatinib vs imatinib for paediatric Ph ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
12 Dec 2019
Study of quadruple combination for induction resistant myeloma reveals novel imm...
Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Study of quadruple combination for induction resistant myeloma reveals novel immune checkpoints ( Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel )
12 Dec 2019
KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )
12 Dec 2019
Updates on REGN1979 in R/R B-cell non-Hodgkins lymphoma
Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
Updates on REGN1979 in R/R B-cell non-Hodgkins lymphoma ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )
12 Dec 2019
Eligibility criteria in acute myeloid leukaemia clinical trials
Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA
Eligibility criteria in acute myeloid leukaemia clinical trials ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )
12 Dec 2019
Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia
Dr Robert Kreitman - National Cancer Institute, Bethesda, USA
Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia ( Dr Robert Kreitman - National Cancer Institute, Bethesda, USA )
12 Dec 2019
Azacitidine plus nivolumab in older adults with AML or MDS
Prof Annette Hay - Queen's University, Ontario, Canada
Azacitidine plus nivolumab in older adults with AML or MDS ( Prof Annette Hay - Queen's University, Ontario, Canada )
12 Dec 2019
Venetoclax chemo combo active and well-tolerated in children with r/r AML
Dr Seth Karol - St. Jude Children’s Research Hospital, Memphis, USA
Venetoclax chemo combo active and well-tolerated in children with r/r AML ( Dr Seth Karol - St. Jude Children’s Research Hospital, Memphis, USA )
12 Dec 2019
Precision medicine treatment in older AML: Results of Beat AML master trial
Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA
Precision medicine treatment in older AML: Results of Beat AML master trial ( Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA )
10 Dec 2019
Older patients with non-Hodgkin lymphoma can be treated successfully with CAR T-...
Dr Karl Kilgore - Avalere Health, Bowie, USA
Older patients with non-Hodgkin lymphoma can be treated successfully with CAR T-cell therapy ( Dr Karl Kilgore - Avalere Health, Bowie, USA )
10 Dec 2019
Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone im...
Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA
Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone improves over time in transplant-eligible newly diagnosed multiple myeloma ( Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA )
10 Dec 2019
CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in pati...
Prof Deepu Madduri - Mount Sinai, New York, USA
CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in patients with multiple myeloma ( Prof Deepu Madduri - Mount Sinai, New York, USA )
10 Dec 2019
Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse ...
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )
10 Dec 2019
Identifying prognostic constellations of driver mutations in acute myeloid leuka...
Dr Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA
Identifying prognostic constellations of driver mutations in acute myeloid leukaemia and myelodysplastic syndromes ( Dr Charles Mullighan -  St. Jude Children's Research Hospital, Memphis, USA )
10 Dec 2019
CANDOR: Triple drug combo delays disease progression in stubborn multiple myelom...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
CANDOR: Triple drug combo delays disease progression in stubborn multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )
10 Dec 2019
Maintenance therapy with CC-486 for acute myeloid leukaemia
Prof Andrew Wei - Monash University, Melbourne, Australia
Maintenance therapy with CC-486 for acute myeloid leukaemia ( Prof Andrew Wei - Monash University, Melbourne, Australia )
10 Dec 2019
Daratumuab, carfilzomib and dexamethasone increases survival in patients with re...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
Daratumuab, carfilzomib and dexamethasone increases survival in patients with relapsed/refractory multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )
10 Dec 2019
Exploring the pathogenesis of AML and myelodysplastic syndromes using genome and...
Dr Ilaria Iacobucci - St. Jude Children's Research Hospital, Memphis, USA
Exploring the pathogenesis of AML and myelodysplastic syndromes using genome and transcriptome sequencing ( Dr Ilaria Iacobucci - St. Jude Children's Research Hospital, Memphis, USA )
10 Dec 2019
QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients wi...
Prof Andrew Wei - Monash University, Melbourne, Australia
QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients with acute myeloid leukaemia in first remission ( Prof Andrew Wei - Monash University, Melbourne, Australia )
10 Dec 2019
Blinatumomab demonstrates superior efficacy compared to chemotherapy in children...
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
Blinatumomab demonstrates superior efficacy compared to chemotherapy in children and young adults with relapsed B-ALL ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )
10 Dec 2019
Multiple myeloma highlights from ASH 2019
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
Multiple myeloma highlights from ASH 2019 ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )
10 Dec 2019
MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractor...
Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia
MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractory chronic lymphocytic leukaemia ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )
9 Dec 2019
Glasdegib in combination with azacitidine in patients with untreated higher-risk...
Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA
Glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes and AML ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )
9 Dec 2019
Addressing the treatment gap for patients with relapsed/refractory primary syste...
Prof Evangelos Terpos and Prof Efstathios Kastritis
Addressing the treatment gap for patients with relapsed/refractory primary systemic AL amyloidosis: TOURMALINE-AL1 trial results ( Prof Evangelos Terpos and Prof Efstathios Kastritis )
9 Dec 2019
Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
9 Dec 2019
Challenges and importance of long-term treatment for newly diagnosed multiple my...
Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin
Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients; community-based trial data ( Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin )
9 Dec 2019
Novel multi-antigen targeted CAR-NK cell for the treatment of B cell malignancie...
Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA
Novel multi-antigen targeted CAR-NK cell for the treatment of B cell malignancies ( Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA )
9 Dec 2019
Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise
Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA
Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise ( Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA )
8 Dec 2019
Evaluating emerging mutations in patients with acute myeloid leukaemia who relap...
Dr Catherine Smith - University of California San Francisco, San Francisco, USA
Evaluating emerging mutations in patients with acute myeloid leukaemia who relapsed while receiving gilteritinib therapy in the ADMIRAL trial ( Dr Catherine Smith - University of California San Francisco, San Francisco, USA )
8 Dec 2019
Maintenance decitabine after intensive therapy for AML in older FLT3-ITD-negativ...
Dr James Foran - Mayo Clinic Florida, Jacksonville, USA
Maintenance decitabine after intensive therapy for AML in older FLT3-ITD-negative patients ( Dr James Foran - Mayo Clinic Florida, Jacksonville, USA )
8 Dec 2019
Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma
Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China
Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )
7 Dec 2019
Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma...
Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA
Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients ( Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA )
7 Dec 2019
CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissio...
Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China
CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissions ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )
7 Dec 2019
Dual-targeted antibody mosunetuzumab elicits durable responses in poor-prognosis...
Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA
Dual-targeted antibody mosunetuzumab elicits durable responses in poor-prognosis non-Hodgkin Lymphoma patients ( Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA )
7 Dec 2019
Multiple myeloma patients treated with BCMA-directed CAR T-cell therapy have hig...
Prof Deepu Madduri - Mount Sinai, New York, USA
Multiple myeloma patients treated with BCMA-directed CAR T-cell therapy have high response rate ( Prof Deepu Madduri - Mount Sinai, New York, USA )
7 Dec 2019
Cellular immunotherapy for B cell cancers shows promise
Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA
Cellular immunotherapy for B cell cancers shows promise ( Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA )
7 Dec 2019